カテゴリ： GlobalData, アメリカ, 企業調査

Janssen Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Janssen Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C2793
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：92
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥34,500見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥69,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥103,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Janssen Pharmaceuticals Inc (Janssen), a subsidiary of Johnson & Johnson is a pharmaceutical company that develops drugs. The company offers medicines for an array of health conditions in therapeutic areas of attention deficit hyperactivity disorder, general medicine, mental health, neurologics, pain management, women’s health, and others. It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer’s disease, epilepsy, migraine prevention and treatment. The company sells its products through a network of distributors across the US. It caters services to cardiovascular & metabolism, immunology, infectious diseases, vaccines, neuroscience,Oncology and other therapeutic areas. Janssen is headquartered in Titusville, New Jersey, the US.

Janssen Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Venture Financing 19
Alios BioPharma Raises US$41 Million In Series B Venture Financing 19
Partnerships 20
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 20
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 21
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 22
Janssen Pharma Enters into Research Partnership with Beacon Discovery 23
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 24
Genomic Health Enters into Research Agreement with Janssen Pharma 25
Cerveau Technologies Enters into Agreement with Janssen Pharma 26
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 27
PeptiDream Enters into Agreement with Janssen Pharma 28
Janssen Pharma Enters into Partnership with Premier 29
Renova Therapeutics Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 31
Karolinska Institutet Partners with Johnson & Johnson Companies 32
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 33
Janssen Pharma Enters into Partnership with Bird Rock Bio 34
DiamiR Enters into Research Agreement with Janssen Pharma 35
Janssen Pharma Enters into Agreement with University of Pennsylvania 36
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 37
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 38
Janssen Pharma Enters into Agreement with University of California, San Diego 39
Cypralis Enters into Research Agreement with Janssen Pharma 40
BlinkBio Enters into Discovery Agreement with Janssen Pharma 41
NeurOp Enters into Research Agreement with Janssen Pharma 42
AC Immune Enters into Research Agreement with Janssen Pharma 43
Alector Enters Into Research Agreement With Janssen Pharma 44
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 45
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 46
Mellitech Enters into Agreement with Janssen Pharma 48
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 49
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 50
Licensing Agreements 51
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 51
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 52
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 53
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 54
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 55
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 56
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 57
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 58
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 59
AC Immune Enters into Licensing Agreement with Janssen Pharma 60
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 61
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 63
Janssen Pharma Enters into Licensing Agreement with BiocerOX 64
Orion Enters Into Licensing Agreement With Janssen Pharma 65
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 66
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 67
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 68
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 69
Shionogi Enters Into Licensing Agreement With Janssen Pharma 71
Depomed Enters Into Licensing Agreement With Janssen Pharma 72
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 73
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 74
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 75
Asset Transactions 77
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 77
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 78
Vivus Acquires Topiramate Related Patents from Janssen Pharma 80
Acquisition 81
Janssen Pharma Acquires XO1 81
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 82
Janssen Pharmaceuticals Inc – Key Competitors 84
Janssen Pharmaceuticals Inc – Key Employees 85
Janssen Pharmaceuticals Inc – Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Recent Developments 87
Legal and Regulatory 87
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 87
Government and Public Interest 88
Feb 21, 2018: New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers 88
Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 89
Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 90
Other Significant Developments 91
Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 91
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92

List of Tables
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Alios BioPharma Raises US$41 Million In Series B Venture Financing 19
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 20
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 21
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 22
Janssen Pharma Enters into Research Partnership with Beacon Discovery 23
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 24
Genomic Health Enters into Research Agreement with Janssen Pharma 25
Cerveau Technologies Enters into Agreement with Janssen Pharma 26
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 27
PeptiDream Enters into Agreement with Janssen Pharma 28
Janssen Pharma Enters into Partnership with Premier 29
Renova Therapeutics Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 31
Karolinska Institutet Partners with Johnson & Johnson Companies 32
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 33
Janssen Pharma Enters into Partnership with Bird Rock Bio 34
DiamiR Enters into Research Agreement with Janssen Pharma 35
Janssen Pharma Enters into Agreement with University of Pennsylvania 36
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 37
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 38
Janssen Pharma Enters into Agreement with University of California, San Diego 39
Cypralis Enters into Research Agreement with Janssen Pharma 40
BlinkBio Enters into Discovery Agreement with Janssen Pharma 41
NeurOp Enters into Research Agreement with Janssen Pharma 42
AC Immune Enters into Research Agreement with Janssen Pharma 43
Alector Enters Into Research Agreement With Janssen Pharma 44
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 45
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 46
Mellitech Enters into Agreement with Janssen Pharma 48
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 49
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 50
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 51
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 52
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 53
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 54
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 55
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 56
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 57
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 58
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 59
AC Immune Enters into Licensing Agreement with Janssen Pharma 60
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 61
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 63
Janssen Pharma Enters into Licensing Agreement with BiocerOX 64
Orion Enters Into Licensing Agreement With Janssen Pharma 65
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 66
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 67
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 68
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 69
Shionogi Enters Into Licensing Agreement With Janssen Pharma 71
Depomed Enters Into Licensing Agreement With Janssen Pharma 72
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 73
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 74
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 75
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 77
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 78
Vivus Acquires Topiramate Related Patents from Janssen Pharma 80
Janssen Pharma Acquires XO1 81
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 82
Janssen Pharmaceuticals Inc, Key Competitors 84
Janssen Pharmaceuticals Inc, Key Employees 85
Janssen Pharmaceuticals Inc, Other Locations 86
Janssen Pharmaceuticals Inc, Subsidiaries 86

List of Figures
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Janssen Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Dhamma Energy：電力：M&Aディール及び事業提携情報
    Summary Dhamma Energy (Dhamma) is an energy services company that develops, operates and invests in solar photovoltaic installations. The company's services cover the technical and financial studies, development and acquisition, construction and commissioning, and operation and maintenance stages of …
  • Beacon Roofing Supply Inc：企業のM&A・事業提携・投資動向
    Beacon Roofing Supply Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Beacon Roofing Supply Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Lebara Group：企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Central European Media Enterprises Ltd.：企業のM&A・事業提携・投資動向
    Central European Media Enterprises Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Central European Media Enterprises Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • Abdullah Al-Othaim Markets Co.
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • European Investment Bank：企業の戦略的SWOT分析
    European Investment Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Genfit SA (GNFT)-医療機器分野：企業M&A・提携分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s product pipeline comprise GFT505, TGFTX1, TGFTX3, TGFTX4, TGFTX5 and SAN/GFT-2. Its TGFTX1 can be …
  • GenomeDx Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary GenomeDx Biosciences Inc (GenomeDx) is a genomic information company developing solutions for prostate cancer treatment and the management of other urologic cancers. The company offers decipher prostate cancer classifier, a transformative genomic test that provides an assessment of tumor agg …
  • NUERNBERGER Beteiligungs-Aktiengesellschaft：企業の戦略・SWOT・財務情報
    NUERNBERGER Beteiligungs-Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report Summary NUERNBERGER Beteiligungs-Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Downer EDI Ltd (DOW)-エネルギー分野：企業M&A・提携分析
    Summary Downer EDI Limited (Downer) is a diversified services company. The company offers wide range of services such as transport infrastructure, engineering, utility, construction, and maintenance., It also provides mining services such as open-cut mining, crushing, underground mining operations, …
  • TETRA Technologies Inc (TTI)：石油・ガス：M&Aディール及び事業提携情報
    Summary TETRA Technologies Inc (TETRA) is an oil and gas company that offers completion fluids and associated products and services. The company’s services comprise compression services, fluid, filtration and tools services, offshore services, production testing, rig cooling services, technology cen …
  • Bourbon SA (GBB)-石油・ガス分野：企業M&A・提携分析
    Summary Bourbon SA (Bourbon) is a provider of marine and subsea services to the oil and gas industry. The company’s services consist of transport and supply of offshore material, floating production, storage and offloading (FPSO) support, anchor handling, towage and offshore positioning, assistance, …
  • Pampa Energia S.A (PAMP)-石油・ガス分野：企業M&A・提携分析
    Summary Pampa Energia S.A. (Pampa) is an integrated energy company. It generates, transmits and distributes electricity. The company produces electricity from thermal, hydro and wind sources. Pampa explores for and produces hydrocarbon products in Argentina, Ecuador and Venezuela; refines diesel, fu …
  • Vior Inc (VIO)：企業の財務・戦略的SWOT分析
    Summary Vior Inc (Vior) is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of gold and silver metal properties in North and Latin America. Its projects comprise Mosseau Gold project, Foothills Rutile project, Vezza-Noyard Go …
  • Syngenta AG：企業の戦略・SWOT・財務分析
    Syngenta AG - Strategy, SWOT and Corporate Finance Report Summary Syngenta AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • United Technologies Corp (UTX)：企業の財務・戦略的SWOT分析
    United Technologies Corp (UTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Orezone Gold Corporation：企業の戦略・SWOT・財務情報
    Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SpectraScience Inc (SCIE)-医療機器分野：企業M&A・提携分析
    Summary SpectraScience Inc (SpectraScience) is a medical device company, which undertakes the design, development, manufacture and marketing of light-based technology products. The company offers its proprietary WavSTAT Optical Biopsy System to diagnose tissue health optically by using light. This s …
  • Culture Landmark Investment Ltd：企業の戦略・SWOT・財務分析
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • JACCS Co Ltd：企業の戦略・SWOT・財務分析
    JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report Summary JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆